2. Pharmacological Treatment of Type 2 Diabetes: Advantages and Dilemmas

Prato, Stefano Del

doi:10.1210/team.9781936704071.ch2

Cited by 2 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The last ten years has broadened our understanding of the benefits of therapy versus the dilemmas that are created by the old and new therapeutic agents. 41 The new approach of individualized care recommended by both the ADA and EASD has been and should be a basis for all therapeutic approaches. 42 Effective therapies have to benefit the patient, be achievable, incorporate the patient’s attitudes and motivations, have minimal side effects, and be affordable.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Type 2 diabetes: the evolution of a disease

Lebovitz

2012

Diabetes & Vascular Disease

View full text Add to dashboard Cite

The heterogeneous nature of type 2 diabetes has become increasingly evident over the last 60 years, and particularly so in the last decade with the increased use of genetic fingerprinting techniques and understanding of environmental influences on the genome. The last decade has seen the expansion of the pharmacological options for the treatment of type 2 diabetes and the burgeoning of large randomized controlled trials. Whilst these trials have been designed to address important issues, many have generated more conundrums, highlighting the need for a diversity of approaches to investigate the pathophysiology of type 2 diabetes and its treatment. See Golden Jubilee article: ‘‘Type 2 diabetes: how far have we come’ by Harold E Lebovitz, published in Br J Diabetes Vasc Dis 2002;2:446-449, © 2002. doi:10.1177/14746514020020060601. http://www.bjdvd.com/content/2/6.toc

show abstract

Section: Introductionmentioning

confidence: 99%

“…A major dilemma in defining therapeutic options for the patient with type 2 diabetes is the evaluation of the risk of the option to its potential benefit. 41,43 This has to be decided between the health care provider and the patient. The following are a few examples of such dilemmas.…”

Section: Introductionmentioning

confidence: 99%

Type 2 diabetes: the evolution of a disease

Lebovitz

2012

Diabetes & Vascular Disease

View full text Add to dashboard Cite

show abstract

Metabolic Surgery for Type 2 Diabetes with BMI <35 kg/m2

Lebovitz

2013

OBES SURG

Self Cite

View full text Add to dashboard Cite

Is bariatric surgery as primary therapy for type 2 diabetes mellitus (T2DM) with body mass index (BMI) <35 kg/m2 justified? Open-label studies have shown that bariatric surgery causes remission of diabetes in some patients with BMI <35 kg/m2. All such patients treated had substantial weight loss. Diabetes remission was less likely in patients with lower BMI than those with higher BMI, in patients with longer than shorter duration and in patients with lesser than greater insulin reserve. Relapse of diabetes increases with time after surgery and weight regain. Deficiencies of data are lack of randomized long-term studies comparing risk/benefit of bariatric surgery to contemporary intensive medical therapy. Current data do not justify bariatric surgery as primary therapy for T2DM with BMI <35 kg/m2.

show abstract

2. Pharmacological Treatment of Type 2 Diabetes: Advantages and Dilemmas

Cited by 2 publications

References 36 publications

Type 2 diabetes: the evolution of a disease

Type 2 diabetes: the evolution of a disease

Metabolic Surgery for Type 2 Diabetes with BMI <35 kg/m2

Contact Info

Product

Resources

About